JP 7
Latest Information Update: 12 Oct 2006
At a glance
- Originator Allos Therapeutics
- Class
- Mechanism of Action Haemoglobin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Hypoxia
Most Recent Events
- 06 Apr 2004 Suspended - Preclinical for Acute hypoxia in USA (unspecified route)
- 31 Mar 2003 No development reported - Preclinical for Acute hypoxia in USA (unspecified route)
- 21 Jul 2000 Preclinical development for Acute hypoxia in USA (unspecified route)